TY 9591
Alternative Names: TY-9591Latest Information Update: 22 Feb 2024
At a glance
- Originator TYK Medicine
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Preclinical Solid tumours
- No development reported Brain metastases
Most Recent Events
- 13 Feb 2024 TYK Medicines initiates a pharmacokinetics phase I trial in healthy chinese subjects in China (PO) (NCT06255951)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Brain metastases in China (Parenteral)
- 17 Aug 2023 Phase-II clinical trials in Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (PO) (NCT05948813)